ABBV · AbbVie Inc.
$208.792026-05-17Sector: Healthcare; Industry: Drug Manufacturers - General; Sub-Industry: Biotechnology
Intrinsic Value Range Comparison · Mulya.ai
R&D capitalized (5yr)Base · active
$171
-18.3% vs market
Mulya.ai vs Analyst IV Comparison?
Mulya.ai IV range ($128 · $313) Analysts Range ($223 · $299) Fundamentals · historical + forward · baseitalics = DCF projection
| Period | Revenue | Rev Gr ? | Ops M% ? | Tax Rate ? | NOPAT ? | Reinvest ? | FCFF ? | WACC% ? | PV FCFF ? | ROIC ? | Inv. Cap ? | EPS ? | P/E |
|---|
| 2021.Q4 | $56.2B | — | 36.0% | 11.1% | $18.0B | $2.7B | $20.6B | 3.7% | — | 16.8% | $107.3B | $6.51 | — |
| 2022.Q4 | $58.1B | 3.3% | 35.2% | 12.1% | $18.0B | $5.2B | $23.2B | 5.5% | — | 18.1% | $91.6B | $6.67 | — |
| 2023.Q4 | $54.3B | -6.4% | 26.5% | 22.0% | $11.2B | $7.7B | $19.0B | 5.4% | — | 13.0% | $80.7B | $2.74 | — |
| 2024.Q4 | $56.3B | 3.7% | 18.3% | 0.0% | $11.9B | −$18.6B | −$6.7B | 6.5% | — | 12.8% | $104.5B | $2.41 | — |
| 2025.Q4 | $61.2B | 8.6% | 30.1% | 35.8% | $11.8B | $5.0B | $16.9B | 5.6% | — | 12.3% | $87.8B | $2.38 | 20.1 |
| italics below = DCF projection · 10yr Rev CAGR: 5.8% |
| 2026.Q4 | $67.1B | +9.8% | 34.0% | 34.3% | $15.0B | −$6.0B | $9.0B | 6.0% | $8.5B | 16.5% | $93.8B | $6.65 | 31.4 |
| 2027.Q4 | $72.3B | +7.7% | 33.4% | 32.7% | $16.3B | −$5.8B | $10.5B | 6.3% | $9.3B | 16.8% | $99.5B | $7.38 | 28.3 |
| 2028.Q4 | $77.6B | +7.3% | 32.9% | 31.1% | $17.6B | −$6.6B | $10.9B | 6.6% | $9.1B | 17.1% | $106.2B | $8.16 | 25.6 |
| 2029.Q4 | $81.7B | +5.3% | 32.3% | 29.5% | $18.6B | −$4.8B | $13.8B | 6.8% | $10.8B | 17.1% | $110.9B | $8.85 | 23.6 |
| 2030.Q4 | $85.9B | +5.1% | 31.2% | 27.9% | $19.3B | −$5.2B | $14.1B | 7.1% | $10.3B | 17.0% | $116.1B | $9.64 | 21.7 |
|
| Term. Yr+ | $111.6B | 4.1% | 31.2% | 20.0% | $27.8B | −$6.2B | $21.6B | 8.6% | $239.7B | 18.4% | — | — | — |
Active scenario IV: $171 (-18.3% vs market)